Date: October 31, 2026

Financial Performance Summary

Quarterly Results (Q2 FY27 vs Q2 FY26)

  • Revenue: ₹2,145 million (up 16% YoY from ₹1,845 million)
  • EBITDA: ₹721 million (up 20% YoY from ₹601 million)
  • EBITDA Margin: 34% (vs 33% in Q2 FY26)
  • PAT: ₹512 million (up 14% YoY from ₹447 million)
  • PAT Margin: 24% (vs 24% in Q2 FY26)
  • EPS: ₹4.33 (up 12% YoY from ₹3.87)
  • PBT: ₹688 million (up 15% YoY from ₹595 million)
  • PBT Margin: 32%

Quarterly Sequential Performance (Q2 FY27 vs Q1 FY27)

  • Revenue: ₹2,145 million (up 12% QoQ from ₹1,917 million)
  • EBITDA: ₹721 million (up 36% QoQ from ₹529 million)
  • PAT: ₹512 million (up 33% QoQ from ₹386 million)
  • EPS: ₹4.33 (up 30% QoQ from ₹3.31)

Half-Yearly Results (H1 FY27 vs H1 FY26)

  • Revenue: ₹4,062 million (up 10% YoY from ₹3,704 million)
  • EBITDA: ₹1,250 million (up 7% YoY from ₹1,165 million)
  • EBITDA Margin: 31% (vs 31% in H1 FY26)
  • PAT: ₹897 million (up 5% YoY from ₹852 million)
  • PAT Margin: 22% (vs 23% in H1 FY26)
  • EPS: ₹7.64 (up 3% YoY from ₹7.44)
  • PBT: ₹1,223 million (up 7% YoY from ₹1,144 million)
  • PBT Margin: 30%

Cost Structure Analysis

Financial Costs

  • Q2 FY27: ₹12 million (vs ₹7 million in Q2 FY26, ₹6 million in Q1 FY27)
  • H1 FY27: ₹18 million (vs ₹15 million in H1 FY26)

Depreciation and Amortization

  • Q2 FY27: ₹109 million (vs ₹101 million in Q2 FY26, ₹99 million in Q1 FY27)
  • H1 FY27: ₹208 million (vs ₹197 million in H1 FY26)

Segment-wise Performance (Q2 FY27)

| Segment | Q2 FY27 Revenue (₹ Mn) | Q2 FY26 Revenue (₹ Mn) | YoY Growth | Q1 FY27 Revenue (₹ Mn) | QoQ Growth |

| Human Nutrition | 1,285 | 1,212 | 6% | 1,158 | 11% |

| Animal Nutrition | 265 | 193 | 37% | 252 | 5% |

| Bio-Processing | 365 | 255 | 43% | 306 | 19% |

| Specialized Manufacturing | 231 | 185 | 25% | 200 | 15% |

Bio-Processing Segment Breakdown (Q2 FY27)

  • Food Business: ₹305 million (48% YoY growth)
  • Non-Food Business: ₹60 million (21% YoY growth)

Geographical Revenue Analysis (Q2 FY27)

Domestic vs International

  • Domestic Sales: ₹1,110 million (52% of total, up 25% YoY)
  • International Sales: ₹1,035 million (48% of total, up 8% YoY)

International Regional Performance (YoY)

  • Americas: 4% growth
  • Asia (ex-India): 6% growth
  • Europe: 10% decline
  • Rest of World: 156% growth

Strategic Initiatives and Business Updates

Human Nutrition Expansion

  • Launched Wellfa nutraceutical brand in India targeting Indian consumers
  • Product range includes immune support, skincare, gut health, metabolism enhancement, detox solutions, weight management, stress relief, and respiratory health
  • Expanding B2C presence through online platforms and digital sales channels

Animal Nutrition Development

  • Conducting trials and research for innovative nutritional products for animal feeds
  • Planning to register and launch additional products in domestic and international markets
  • Expanding sales and marketing teams across USA, MENA, and Asian regions
  • Appointing new distributors in international markets

Probiotics Expansion

  • Introducing additional probiotic products in Human Nutrition segment focusing on immunity enhancement, active health foods, gut health, and nutraceutical applications
  • Launching new products in Animal Nutrition segment aimed at boosting immunity, improving digestion, and enhancing nutritional value of animal feed

Bio Catalysis Development

  • Developing biocatalysis for API manufacturers with targeted enzymatic solutions
  • Products at various development stages, with some in advanced plant-level trials with API manufacturers
  • Focus on reducing energy consumption, processing time, and chemical usage

Baking Industry Expansion

  • Submitted 15 dossiers to European Food Safety Authority (EFSA), received positive opinions for 9
  • Expanding presence across Europe, Americas, and other global markets in baking industry

Research & Development

  • Making substantial investments in state-of-the-art R&D infrastructure
  • Expanding application portfolio across various industries
  • Strengthening R&D team to support growth and drive future advancements

Inorganic Growth Strategy

  • Maintains zero-debt status with all acquisitions financed through internal accruals
  • Completed four acquisitions over past nine years
  • Continuing to explore strategic acquisition opportunities to enhance frontend marketing capabilities, expand geographical footprint, strengthen product portfolio, and bolster B2C business

Conference Call Details

  • Earnings conference call scheduled for November 3, 2026, at 16:00 Hours IST
  • Transcript will be available in Investor Relations section on company website: www.advancedenzymes.com